Secondary Cytoreductive Surgery Resulting in Maximal Tumor Resection Improves Overall Survival In Recurrent Ovarian Cancer

MedPage Today  (2/23, Bankhead) reported, “Secondary cytoreductive surgery (SCS) for recurrent ovarian cancer significantly improved overall survival…when surgery achieved maximal tumor resection, a large meta-analysis showed.” According to the results  published in the Journal of Clinical Oncology, “pooled data from 36 studies showed a death rate of 44.2%, which decreased substantially with increasing rates of complete and optimal SCS.”